Navigation Links
Insmed to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference
Date:8/14/2012

MONMOUTH JUNCTION, N.J., Aug. 14, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today announced that Timothy Whitten, President and Chief Executive Officer, will be presenting a corporate overview at the 2012 Wedbush PacGrow Life Sciences Management Access Conference in New York on Wednesday, August 15, 2012, at 8:35 AM ET.

A live audio webcast will be made available on Insmed's website, http://www.insmed.com.  The webcast will also be archived for 90 days.

About Insmed

Insmed Incorporated is a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, with a particular focus on orphan diseases.  Insmed's core expertise is the development of inhaled antibiotic therapy delivered via proprietary advanced liposomal pulmonary technology.  For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to our financial position, our estimates regarding our capital requirements and our needs for additional financing, our ability to access additional funds under the Hercules loan agreement, results of operations, the status, results and timing of results of pre-clinical studies and clinical trials and pre-clinical and clinical data described herein, the timing of and costs associated with pre-clinical studies and clinical trials, the development of our products, our estimates of the size of the potential markets for our product candidates, and the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  Our results may be affected by such factors as the receipt and timing of U.S. Food and Drug Administration and other regulatory reviews and approvals, if at all, competitive developments affecting our product development, delays in product development or clinical trials, and patent disputes involving currently developing products.  The risks and uncertainties include, without limitation, we may experience unexpected regulatory actions, delays or requests, our future clinical trials may not be successful, we may be unsuccessful in developing our product candidates or receiving necessary regulatory approvals, we may experience delays in our product development or clinical trials, our product candidates may not prove to be commercially successful, our expenses may be higher than anticipated, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2011 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.  Investors are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:  
Brian Ritchie – FTI Consulting  
212-850-5683  
brian.ritchie@fticonsulting.com 

Media Contact:  
Irma Gomez-Dib – FTI Consulting  
212-850-5761 
irma.gomez-dib@fticonsulting.com


'/>"/>
SOURCE Insmed Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceutical Industry Veteran Al Altomari Elected To Insmeds Board Of Directors
2. Insmed Announces Planned Departure Of Chief Financial Officer
3. Insmed to Host 2012 Second Quarter Earnings Conference Call
4. Insmed To Present At JMP Securities 7th Annual Healthcare Conference
5. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
6. Insmed Announces First Quarter 2012 Financial Results
7. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
8. Insmed to Host 2012 First Quarter Earnings Conference Call
9. Receptos to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference
10. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
11. HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... Corp., also known as ,The Epigenetics Company, announced today the release of ... using the myDNAge ™ test. Based on Horvath,s Clock, so named ... biostatistics at the David Geffen School of Medicine at UCLA ... ™ technology is used to analyze DNA methylation patterns of over ... Epigenetic ...
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... TRIANGLE PARK, N.C. , July 10, 2017 /PRNewswire/ ... a $5m Convertible Note to support the development of ... by Tencent Holdings Limited, a leading Chinese Internet services ... This funding will advance multiple infectious disease product programs ... Founded by Dr. ...
Breaking Medicine Technology:
(Date:7/20/2017)... Valencia, Calif. (PRWEB) , ... July 19, 2017 , ... ... has acquired the Minnesota based Health IT business unit of Constellation Inc., a move ... an already established base of operations in St. Louis, the acquisition is expected to ...
(Date:7/20/2017)... California (PRWEB) , ... July 19, 2017 , ... A ... that most successful weight loss surgery patients who had received a body contouring procedure ... health and beauty clinic Beverly Hills Physicians (BHP), which provides both types of procedures, ...
(Date:7/20/2017)... ... ... “Lucky the Buffalo and Her Adventures”: a collection of heartwarming children’s stories. “Lucky the ... Bieniek Jr. was born in Toledo, Ohio. He attended Woodward High School. He ... married to a brilliant woman with a caring heart named Tiina, who is a hospice ...
(Date:7/18/2017)... ... July 18, 2017 , ... ClinicalTrials.gov and the ... You Need to Consider?, **An FDAnews Webinar**, Aug. 2, 2017 — 1:30 p.m. ... “Final Rule for Clinical Trials Registration and Results Information,” is a head-scratcher. After ...
(Date:7/18/2017)... ... July 18, 2017 , ... An inventor from Anacortes, ... "Due to menopause, I have frequent hot flashes, and I suffer from anxiety and ... way to keep cool while out and about." INSTA-FAN meets that need. , This ...
Breaking Medicine News(10 mins):